The 'One Companion Diagnostic - One Drug' Paradigm is Not Fit For Purpose - Diaceutics

The ‘One Companion Diagnostic – One Drug’ Paradigm is Not Fit For Purpose

April 4th, 2013

Joanna Przewrocka

The cancer therapy market is evolving dynamically. We understand more and more about cancer biology and we are now able to develop drugs that selectively target the molecular drivers of tumorgenesis. Joanna Przewrocka examines a development in the field – polypharmacology – in relation to the paradigm of ‘one companion diagnostic – one drug’.  

All this sounds great—approaching cancer from multiple angles using cocktails consisting of many targeted agents in order to suppress it more effectively—but is this at all feasible within the current cost structures? Targeted therapies are priced at premium rates similar to those charged for therapies previously designated with orphan or small market status. If we use a cocktail of targeted agents do we also combine the prices of all the drugs used? Will payers be able to cope with the costs?

Although researchers are eager to test the targeted therapy combinations, they are confronted with many barriers. One is commercial competition. Pharmaceutical companies worry that side effects that emerge during combination therapy may influence the commercialization of a drug that would be otherwise safe when used alone, especially if the agents are still under development and have not yet been approved. It is difficult to predict the efficacy and toxicity of rationally designed drug cocktails in pre-clinical models, even when the individual agents have already shown clinical anticancer activity. For example, pre-clinical experiments supported the combination of gefitinib and trastuzumab in breast cancer, erlotinib and bevacizumab in renal cell carcinoma, and cetuximab and bevacizumab in colorectal cancer. However, efficacy of all of these combinations failed expectations in clinical trials.

Cocktails consisting of many targeted agents, particularly ones that target different pathways used by normal cells, can also induce unacceptable side effects. Lung cancer researcher Jeffrey Engelman thinks that for this reason, patients will be able to tolerate a cocktail only for a short period of time. He suggests putting patients on a single drug, then intermittently giving them a ‘pulse’ of a cocktail for several days.

What about the diagnostics? The ‘one companion diagnostic – one drug’ paradigm may not work out so well due to a couple of reasons.

First of all, cancer is extremely heterogenic. This can be observed not only between different types of cancer, but also between tumors of two different patients with the same type of cancer, between two metastatic lesions within one patient, and even between two different cells within the same tumor. Although some tumor types are associated predominantly with abnormal activity of a single kinase (such as in chronic myeloid leukaemia, where 95 per cent of patients have a chromosome abnormality known as Philadelphia chromosome, that results in the translation of bcr-abl fusion proteins), it is not as obvious in other cancer types. For example, a study by Sequist et al. (2011) scanned genetic profiles of tumors from 552 non-small cell lung cancer patients and identified the presence of different mutations (KRAS, EGFR, translocations involving ALK, BRAF, TP53, PIK3CA, CTTNB1, NRAS, HER2, IDH1), sometimes occurring simultaneously with others. Therefore,the entire cancer genome should be scanned to identify all known mutation and tailor molecularly guided therapies.

Secondly, genomes most probably would have to be scanned multiple times to monitor disease progression, as cancer cells are constantly evolving and developing resistance to anti-cancer drugs. A 2011 study published in Science Translational Medicine (STM) by Engelman’s group on non-small cell lung cancer, illustrates this complexity by analyzing 37 biopsy samples from patients with the EGFR mutation who were given Iressa or Tarceva and later became resistant. Although some resistance mutations were known, others were new, and for 30 per cent of the samples his team could not identify the mechanism. Some tumors even morphed into a different type of lung cancer that requires an entirely different treatment. In addition, biopsies from three patients collected during the course of treatment showed that some tumors that developed resistance mutations later lost them. Engelman’s STM study suggests that clinicians would need to constantly biopsy patients and devise one complex cocktail after another, each tailored to a patient’s evolving tumors.

Next-generation sequencing (NGS) technologies (as opposed to first-generation dideoxy ‘Sanger’) have the ability to massively parallelize the sequencing of millions of DNA templates and are now considered by many laboratories for routine diagnostic use. Compared with other sequencing methods NGS has improved sensitivity, speed and cost. There are currently [2013] three companies offering NGS platforms: Roche, Illumina and Life Technologies. While those commercial platforms are readily available, the analysis of the NGS data is not a simple task and could potentially become a challenge when implementing NGS into standard clinical practice. There are several commercial analysis software programs, some of which are provided by the platform providers. There are multiple steps involved in transforming raw sequence reads into a final list of clinically useful variants. Several different algorithms have to be used in order to improve upon base calling accuracy and reduce systematic errors, read alignment (e.g., BWA,  AQ, Bowtie and Novoalign algorithms), and separate real variations from sequencing noise (e.g., Bayesian algorithms).

All in all, the list of novel cancer biomarkers will hopefully be expanding and cancer research will lead to new solutions and strategies. Pharmaceutical companies will soon need to accommodate for the increasing speed of cancer research, which might involve abandoning the concepts of high price tags for targeted therapies and the ‘one drug – one companion diagnostic’ paradigm which don’t appear to be sustainable in the long run.


  1. Fleming N. Multiple gene test allows more targeted treatment of cancer. The Guardian, Wednesday 9 November 2011
  2. Katayama R. et al. (2012) Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Science Translational Medicine.  4 (120)
  3. Knight Z.A., H. Lin, K.M. Shokat (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews. Cancer. 10(2):130-7.
  4. Meldrum, C., Doyle, M. A, & Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. The Clinical Biochemist. Reviews / Australian Association of Clinical Biochemists, 32(4), 177–95.
  5. Sequist L. V. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology.
  6. Sequist, L. V, Waltman, B. a, Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., et al. (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine, 3(75).
  7. Stegh, A.H. (2013) Toward personalized cancer nanomedicine – past, present, and future. Integrative Biology: Quantitative Biosciences from Nano to Macro. 5(1):48-6.


View all blogs

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports

Case Studies

View all case studies


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications